Christopher Beynon1, Anna Potzy2, Oliver W Sakowitz2, Andreas W Unterberg2. 1. Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany. Electronic address: christopher.beynon@med.uni-heidelberg.de. 2. Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany.
Abstract
OBJECTIVES: Despite several advantages of the novel anticoagulant rivaroxaban compared with vitamin K antagonists (VKA), its lack of specific antidotes to reverse anticoagulant effects may increase the risk profile of patients with bleeding complications. The purpose of this study was to analyze the effects of pre-injury treatment with rivaroxaban on patients with mild traumatic brain injury (TBI) and traumatic intracranial haemorrhage (tICH). METHODS: A total of 70 patients with tICH after mild TBI were included in this retrospective analysis and were categorized into three groups: group A (no antithrombotics n=37), group B (antiplatelet medication n=22, VKA=5), and group C (rivaroxaban n=6). Medical charts were reviewed for baseline characteristics, laboratory values, intracranial haemorrhage, repeated computed tomography (CT) scans, re-haemorrhage, Glasgow Coma Scale (GCS) scores and in-hospital mortality. RESULTS: No significant differences were observed for baseline characteristics. The rate of re-haemorrhage was significantly higher in group C (50%) than in group A (11%) (p<0.05). Two patients died and both had been treated with rivaroxaban which resulted in a significantly higher mortality rate of 33% in group C compared with groups A (0%) and B (0%). No significant differences were observed for GCS at discharge and length of hospital stay between survivors of groups A-C. CONCLUSIONS: Despite major limitations of retrospective design and small patient numbers, our results suggest that rivaroxaban may exacerbate intracranial haemorrhage in patients with mild TBI. Further studies are needed to characterize the risk profile of this drug in patients with tICH.
OBJECTIVES: Despite several advantages of the novel anticoagulant rivaroxaban compared with vitamin K antagonists (VKA), its lack of specific antidotes to reverse anticoagulant effects may increase the risk profile of patients with bleeding complications. The purpose of this study was to analyze the effects of pre-injury treatment with rivaroxaban on patients with mild traumatic brain injury (TBI) and traumatic intracranial haemorrhage (tICH). METHODS: A total of 70 patients with tICH after mild TBI were included in this retrospective analysis and were categorized into three groups: group A (no antithrombotics n=37), group B (antiplatelet medication n=22, VKA=5), and group C (rivaroxaban n=6). Medical charts were reviewed for baseline characteristics, laboratory values, intracranial haemorrhage, repeated computed tomography (CT) scans, re-haemorrhage, Glasgow Coma Scale (GCS) scores and in-hospital mortality. RESULTS: No significant differences were observed for baseline characteristics. The rate of re-haemorrhage was significantly higher in group C (50%) than in group A (11%) (p<0.05). Two patients died and both had been treated with rivaroxaban which resulted in a significantly higher mortality rate of 33% in group C compared with groups A (0%) and B (0%). No significant differences were observed for GCS at discharge and length of hospital stay between survivors of groups A-C. CONCLUSIONS: Despite major limitations of retrospective design and small patient numbers, our results suggest that rivaroxaban may exacerbate intracranial haemorrhage in patients with mild TBI. Further studies are needed to characterize the risk profile of this drug in patients with tICH.
Authors: Christopher Beynon; Steffen Brenner; Alexander Younsi; Timolaos Rizos; Jan-Oliver Neumann; Johannes Pfaff; Andreas W Unterberg Journal: Neurocrit Care Date: 2019-04 Impact factor: 3.210
Authors: Carl Marincowitz; Fiona E Lecky; William Townend; Aditya Borakati; Andrea Fabbri; Trevor A Sheldon Journal: J Neurotrauma Date: 2018-01-11 Impact factor: 5.269
Authors: Lukas Leitner; Jasmin Helena El-Shabrawi; Gerhard Bratschitsch; Nicolas Eibinger; Sebastian Klim; Andreas Leithner; Paul Puchwein Journal: Arch Orthop Trauma Surg Date: 2020-07-23 Impact factor: 3.067
Authors: Charlie J Nederpelt; Leon Naar; Karien Meier; Suzanne F M van Wijck; Pieta Krijnen; George C Velmahos; Haytham M A Kaafarani; Martin G Rosenthal; Inger B Schipper Journal: Eur J Trauma Emerg Surg Date: 2022-03-10 Impact factor: 2.374
Authors: Abid D Khan; Anna J Elseth; Jacqueline A Brosius; Eliza Moskowitz; Sean C Liebscher; Michael J Anstadt; Julie A Dunn; John H McVicker; Thomas Schroeppel; Richard P Gonzalez Journal: Trauma Surg Acute Care Open Date: 2020-05-28